Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for thrombotic thrombocytopenic purpura — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for thrombotic thrombocytopenic purpura is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
prostaglandin-endoperoxide synthase 2 (PTGS2) — PTGS2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 5F1A · 2.38 Å · ligand 2-HYDROXYBENZOIC ACID (SAL). Experimental structure, not a prediction.
Thrombotic thrombocytopenic purpura is described as an infrequent, sporadic, and historically highly fatal syndrome. A 1981 review states that recent advances in therapy and insight into pathogenesis had dramatically changed its once poor prognosis. A 1999 review notes that historically the mortality rate approached 100%, but by the 1980s new therapy was instituted with a vast improvement in survival to 90%. The exact pathogenesis of TTP remained elusive at that time.
A 1985 study treated 7 patients with plasma exchanges and antiplatelet drugs. 6 of these 7 patients were cured. The authors underline the low predictive value of the initial response to therapy, and state that the clinical and biological status on day 12 seems to have the best predictive value for the final outcome. They encourage continuing plasma exchanges until day 12, whatever the initial response.
The 1999 review attributes improved outcome to increased awareness of symptomatology leading to earlier diagnosis, better supportive care, and effective therapy with plasma exchange. It states that prompt diagnosis and treatment can lead to a critical difference in clinical outcome. No controlled trial data comparing plasma exchange to other interventions is presented in these abstracts, and no drug other than antiplatelet agents is mentioned in the patient data. What is still missing is prospective randomised evidence that isolates the effect of plasma exchange from concurrent supportive care, and any stratification of patients by underlying aetiology or ADAMTS13 activity, which was not yet described in these reports.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThrombotic thrombocytopenic purpura (TTP) is an infrequent, sporadic, and highly fatal syndrome. Recent advances in therapy and insight into the pathogenesis of this disorder have dramatically changed its once poor prognosis. A reappraisal of the diagnosis, pathogenesis, and treatment of TTP is the subject of this article. (<i>JAMA</i>1981;246:1243-1246)
https://doi.org/10.1001/jama.1981.03320110053031Abstract7 patients were treated by plasma exchanges and antiplatelet drugs for thrombotic thrombocytopenic purpura (TTP). The effectiveness of therapy was reviewed daily and retrospectively estimated on day 3, d6, d9, and d12. 6 of these 7 patients were cured. The low predictive value of the initial response to therapy is underlined. The clinical and biological status on d12 seems to have the best predictive value for the final outcome. These data encourage us to continue the plasma exchanges until d12, whatever the initial response to therapy in TTP.
https://doi.org/10.1111/j.1600-0609.1985.tb02249.xAbstractHistorically, the mortality rate of thrombotic thrombocytopenic purpura (TTP) approached 100%. However, by the 1980's, new therapy was instituted with a vast improvement in survival to 90%. The exact pathogenesis of TTP remains elusive. Yet, despite incomplete understanding of the pathophysiology, outcome has improved due to increased awareness of the symptomatology leading to earlier diagnosis and better supportive care, in addition to effective therapy with plasma exchange. TTP represents a disease in which prompt diagnosis and treatment can lead to a critical difference in clinical outcome.
https://doi.org/10.1080/10245332.1999.11746472Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
